Helen Frankenthaler Foundation

Protease-resistant neurotensin

Comparison of N-Terminal Modifications on Neurotensin(8−13) Analogues Correlates Peptide Stability but Not Binding Affinity with in Vivo Efficacy

Article March 16, 2009

Authors

  • Kevin S. Orwig
  • McKensie R. Lassetter
  • M. Kyle Hadden
  • Thomas A. Dix

Journal Information

Journal of Medicinal Chemistry

Cite this: J. Med. Chem. 2009, 52, 7

Published March 16, 2009

research-article

Copyright © 2009 American Chemical Society

Article Views

2306

Altmetric

3

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.

Citations are the number of other articles citing this article, calculated by Crossref and updated daily.

The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online.

Abstract

Neurotensin(8−13) and two related analogues were used as model systems to directly compare various N-terminal peptide modifications representing both commonly used and novel capping groups. Each N-terminal modification prevented aminopeptidase cleavage but surprisingly differed in its ability to inhibit cleavage at other sites, a phenomenon attributed to long-range conformational effects. None of the capping groups were inherently detrimental to human neurotensin receptor 1 (hNTR1) binding affinity or receptor agonism. Although the most stable peptides exhibited the lowest binding affinities and were the least potent receptor agonists, they produced the largest in vivo effects. Of the parameters studied only stability significantly correlated with in vivo efficacy, demonstrating that a reduction in binding affinity at NTR1 can be countered by increased in vivo stability.

ACS Publications

Copyright © 2009 American Chemical Society

Supporting Information

General experimental procedures; synthesis schemes 1−4; serum degradation standard curves; analytical data and experimental procedures for compounds 19, 22, 25, and 28; analytical HPLC analysis and MALDI-TOF data for each of the target peptides. This material is available free of charge via the Internet.

  • jm801072v_si_001.pdf (25.0 MB)
Terms & Conditions

Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use. Permission may be obtained from ACS for other uses through requests via the RightsLink permission system.

Cited By

This article is cited by 34 publications.

No.Citation Details
1.Jolien De Neve, Émile Breault, Santo Previti, et al. Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics. ACS Pharmacology & Translational Science 2024, 7 (9), 2784-2798.
2.Lisa Schindler, Günther Bernhardt, Max Keller. Modifications at Arg and Ile Give Neurotensin(8–13) Derivatives with High Stability and Retained NTS1 Receptor Affinity. ACS Medicinal Chemistry Letters 2019, 10 (6), 960-965.
3.Emmanuelle Rémond, Charlotte Martin, Jean Martinez, and Florine Cavelier. Silicon-Containing Amino Acids: Synthetic Aspects, Conformational Studies, and Applications to Bioactive Peptides. Chemical Reviews 2016, 116 (19), 11654-11684.
4.Simone Maschauer, Jürgen Einsiedel, Harald Hübner, Peter Gmeiner, and Olaf Prante. 18F- and 68Ga-Labeled Neurotensin Peptides for PET Imaging of Neurotensin Receptor 1. Journal of Medicinal Chemistry 2016, 59 (13), 6480-6492.
5.Allison Faig, Timothy D. Arthur, Patrick O. Fitzgerald, et al. Biscationic Tartaric Acid-Based Amphiphiles: Charge Location Impacts Antimicrobial Activity. Langmuir 2015, 31 (43), 11875-11885.
6.Prompong Pienpinijtham, Edyta Proniewicz, Younkyoo Kim, et al. Molecular Orientation of Neurotensin and Its Single-Site Mutants on a Colloidal Silver Surface: SERS Studies. The Journal of Physical Chemistry C 2012, 116 (31), 16561-16572.
7.Edyta Podstawka-Proniewicz, Andrzej Kudelski, Younkyoo Kim, and Leonard M. Proniewicz. Structure and Binding of Specifically Mutated Neurotensin Fragments on a Silver Substrate: Vibrational Studies. The Journal of Physical Chemistry B 2011, 115 (21), 7097-7108.
8.Jürgen Einsiedel, Cornelia Held, Maud Hervet, et al. Discovery of Highly Potent and Neurotensin Receptor 2 Selective Neurotensin Mimetics. Journal of Medicinal Chemistry 2011, 54 (8), 2915-2923.
9.Francis M. Hughes, Jr., Brooke E. Shaner, Lisa A. May, et al. Identification and Functional Characterization of a Stable, Centrally Active Derivative of the Neurotensin (8−13) Fragment as a Potential First-in-Class Analgesic. Journal of Medicinal Chemistry 2010, 53 (12), 4623-4632.
10.Lotfi Ferhat, Rabia Soussi, Maxime Masse, et al. A peptide-neurotensin conjugate that crosses the blood-brain barrier induces pharmacological hypothermia associated with anticonvulsant, neuroprotective, and anti-inflammatory properties following status epilepticus in mice. eLife 2025, 13.